Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share

The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty.

See why the elites are pouring billions into gold.

Paul Burgess Biography and Net Worth

Chief Business Development and Strategic Operations Officer of Cerevel Therapeutics

Paul Burgess is Cerevel’s Chief Business Development and Strategic Operations Officer.

Prior to joining Cerevel, Mr. Burgess was the chief operating officer and chief legal officer of Translate Bio. At Translate Bio, he led business development, legal, program management, quality, technical operations and partner collaborations. Mr. Burgess joined Translate Bio in 2015 and remained until 2021, when the company was sold to Sanofi for $3.2 billion.

Paul Burgess is a biotechnology executive with over 20 years of experience working at both start-up companies and larger pharmaceutical organizations. Prior to Translate Bio, Mr. Burgess worked in a legal role at a number of companies including Scholar Rock, Civitas Therapeutics, BIND Therapeutics and Transform Pharmaceuticals. Mr. Burgess also previously worked in the lab at Genetics Institute.

Mr. Burgess earned his B.S. from Merrimack College and an M.S. in Pharmacology from Northeastern University. He also received his J.D. from Northeastern University School of Law.

What is Paul D. Burgess' net worth?: The estimated net worth of Paul D. Burgess is at least $929,243.60 as of August 4th, 2023. Mr. Burgess owns 21,880 shares of Cerevel Therapeutics stock worth more than $929,244 as of April 27th. This net worth approximation does not reflect any other assets that Mr. Burgess may own. Learn More about Paul D. Burgess' net worth.
How do I contact Paul D. Burgess?: The corporate mailing address for Mr. Burgess and other Cerevel Therapeutics executives is 1535 Rancho Conejo Blvd, THOUSAND OAKS, CA 91320-1440, United States. Cerevel Therapeutics can also be reached via phone at 844-304-2048 and via email at [email protected]. Learn More on Paul D. Burgess' contact information.
Has Paul D. Burgess been buying or selling shares of Cerevel Therapeutics?: Paul D. Burgess has not been actively trading shares of Cerevel Therapeutics during the last ninety days. Most recently, on Friday, August 4th, Paul D. Burgess bought 21,880 shares of Cerevel Therapeutics stock. The stock was acquired at an average cost of $22.93 per share, with a total value of $501,708.40. Following the completion of the transaction, the insider now directly owns 21,880 shares of the company's stock, valued at $501,708.40. Learn More on Paul D. Burgess' trading history.
Who are Cerevel Therapeutics' active insiders?: Cerevel Therapeutics' insider roster includes Scott Akamine (Chief Legal Officer and Corporate Secretary), Susan Altschuller (CFO), Paul Burgess (Chief Business Development and Strategic Operations Officer), Anthony Coles (Director), Kenneth DiPietro (Insider), Deval Patrick (Director), Ronald Renaud, Jr. (CEO), John Renger (Insider), Ramiro Sanchez (Insider), and Gabrielle Sulzberger (Director). Learn More on Cerevel Therapeutics' active insiders.
Are insiders buying or selling shares of Cerevel Therapeutics?: In the last year, Cerevel Therapeutics insiders bought shares 4 times. They purchased a total of 6,462,597 shares worth more than $147,510,898.72. In the last year, insiders at the biotechnology company sold shares 18 times. They sold a total of 625,260 shares worth more than $21,054,440.60. The most recent insider tranaction occured on March, 4th when Director N Anthony Coles sold 50,000 shares worth more than $2,050,500.00. Insiders at Cerevel Therapeutics own 5.1% of the company. Learn More about insider trades at Cerevel Therapeutics.
Information on this page was last updated on 3/4/2024.

Paul D. Burgess Insider Trading History at Cerevel Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/4/2023	Buy	21,880	$22.93	$501,708.40	21,880

Paul D. Burgess Buying and Selling Activity at Cerevel Therapeutics

Cerevel Therapeutics Company Overview

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $42.47

$41.93

$42.49

50 Day Range

MA: $41.86

$40.88

$42.57

2 Week Range

Now: $42.47

$19.59

$43.59

Volume

679,080 shs

Average Volume

1,471,547 shs

Market Capitalization

$7.71 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.48